Decoy Therapeutics Inc. Common Stock (DCOY)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable economics, honest accounting, and a margin of safety. Decoy Therapeutics does not fit that mold. It is a pre-clinical biotech with 11 employees and an early-stage peptide platform; there is no marketed product and no proven moat. The filed numbers show losses in each of the last four years. In fiscal year 2025, the year ended 2025-12-31, net income was -$12.5M and diluted EPS was -$129.10. In fiscal year 2024, the year ended 2024-12-31, net income was -$5.6M; in fiscal year 2023, the year ended 2023-12-31, it was -$12.5M. Most periods show no revenue; the only filed revenue I see is $227,629 in fiscal Q2 2026, the quarter ended 2026-06-30, alongside a -$2.4M net loss and -$4.46 diluted EPS. That tiny revenue line does not cover the burn. FairStock's trailing free cash flow is -$8.9M, and its FCF yield is -1100.9% on an $812,429 market cap at the 2026-10-13 close. The Piotroski F-Score of 1/9 and Altman Z-Score of -14.78 point to financial fragility, while ROE of -827.77% confirms how little capital is being productively employed. The quoted P/B of 0.15 and Graham Number of $48.25 might suggest deep value, but those calculations are unreliable when earnings are negative and the company is burning cash. Beta of 0.64 is low, but the 52-week range of $1.21 to $54.00 shows violent speculation. The FairStock Score of 36/100 and no Peter Lynch category, because of four straight loss years, fit my view: this is a lottery ticket on science, not a Buffett-style compounding machine. I would need evidence of sustainable revenue, partnership validation, and a cash runway before calling it an investment rather than a speculation.

In plain English: Decoy Therapeutics is a tiny early-stage drug research company with 11 employees working on peptide-based treatments. It has almost no revenue and has lost money in each of the last four years, so the business looks very weak and highly speculative. The stock closed at $1.24 on 2026-10-13, but with ongoing losses and negative cash flow, the low price alone does not make it look like a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer